Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 09 2021
Historique:
received: 10 02 2021
revised: 10 05 2021
accepted: 17 06 2021
pubmed: 26 6 2021
medline: 5 4 2022
entrez: 25 6 2021
Statut: ppublish

Résumé

The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications. We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%. Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12-1.59), 1.40, 95% CI (1.14-1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells. This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine.

Identifiants

pubmed: 34168047
pii: 1078-0432.CCR-21-0529
doi: 10.1158/1078-0432.CCR-21-0529
pmc: PMC8974433
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4768-4780

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
J Clin Oncol. 2019 Aug 1;37(22):1876-1885
pubmed: 31042420
Cell Rep. 2019 Nov 19;29(8):2164-2174.e5
pubmed: 31747591
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Clin Cancer Res. 2021 Jan 1;27(1):120-130
pubmed: 33109741
Nat Commun. 2019 Mar 22;10(1):1333
pubmed: 30902996
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Nat Genet. 2020 Nov;52(11):1208-1218
pubmed: 33128048
Nat Med. 2020 Apr;26(4):566-576
pubmed: 32251400
Lancet Oncol. 2014 Jul;15(8):862-73
pubmed: 24928083
J Clin Oncol. 2020 Jun 20;38(18):2053-2061
pubmed: 32343640
Nat Genet. 2020 Jul;52(7):709-718
pubmed: 32601473
Clin Cancer Res. 2016 Aug 15;22(16):4057-66
pubmed: 26994146
Clin Cancer Res. 2017 Dec 1;23(23):7209-7216
pubmed: 28939741
Cancer Res. 2021 Jan 15;81(2):268-281
pubmed: 33148662
Bioinformatics. 2013 Sep 1;29(17):2211-2
pubmed: 23825367
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922790
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Oncotarget. 2016 Mar 1;7(9):10051-63
pubmed: 26840267
Nat Genet. 2020 Jun;52(6):594-603
pubmed: 32451460
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
Cancer Cell. 2020 Apr 13;37(4):471-484
pubmed: 32289271
Ann Oncol. 2018 May 1;29(5):1227-1234
pubmed: 29518181
Clin Cancer Res. 2019 Jul 15;25(14):4431-4442
pubmed: 31004000
Nat Commun. 2015 Apr 30;6:7002
pubmed: 25926053
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Bioinformatics. 2018 Jun 1;34(11):1868-1874
pubmed: 29360996
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Clin Cancer Res. 2016 Aug 15;22(16):4095-104
pubmed: 27151745
Nature. 2014 Apr 3;508(7494):113-7
pubmed: 24695311
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040692
Sci Rep. 2019 Mar 14;9(1):4542
pubmed: 30872730

Auteurs

Laetitia Marisa (L)

Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.

Yuna Blum (Y)

Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.

Julien Taieb (J)

Institut du cancer Paris CARPEM, AP-HP, European Georges Pompidou Hospital, Paris, France.
Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.

Mira Ayadi (M)

Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.

Camilla Pilati (C)

Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.

Karine Le Malicot (K)

Fédération Francophone de Cancérologie Digestive, INSERM, Université de Bourgogne et Franche Comté, Dijon, France.

Côme Lepage (C)

Fédération Francophone de Cancérologie Digestive, INSERM, Université de Bourgogne et Franche Comté, Dijon, France.
Hepatogastroenterology and Digestive Oncology department, CHU Dijon, Dijon, France.

Ramon Salazar (R)

Catalan Institute of Oncology (IDIBELL), Universitat de Barcelona, CIBERONC, Spanish Gastrointestinal Tumors TTD Group, Barcelona, Spain.

Daniela Aust (D)

Institute for Pathology, University Hospital Carl Gustav Carus, Dresden, Germany.

Alex Duval (A)

Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, Equipe Instabilité des Microsatellites et Cancer, équipe labellisé par la Ligue Nationale contre le Cancer, Paris, France.

Hélène Blons (H)

Institut du cancer Paris CARPEM, AP-HP, European Georges Pompidou Hospital, Paris, France.
Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.

Valérie Taly (V)

Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.

David Gentien (D)

Curie Institute, PSL Research University, Translational Research Department, Genomics Platform, Paris, France.

Audrey Rapinat (A)

Curie Institute, PSL Research University, Translational Research Department, Genomics Platform, Paris, France.

Janick Selves (J)

Centre de Recherche en Cancérologie de Toulouse, INSERM, Université Toulouse III, Department of Pathology, CHU Toulouse, Toulouse, France.

Sophie Mouillet-Richard (S)

Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.

Valérie Boige (V)

Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.
Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Jean-François Emile (JF)

Department of Pathology, AP-HP, Hôpital Ambroise Paré, Boulogne-Billancourt, France.

Aurélien de Reyniès (A)

Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France. pierre.laurent-puig@parisdescartes.fr aurelien.dereynies@ligue-cancer.net.

Pierre Laurent-Puig (P)

Institut du cancer Paris CARPEM, AP-HP, European Georges Pompidou Hospital, Paris, France. pierre.laurent-puig@parisdescartes.fr aurelien.dereynies@ligue-cancer.net.
Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH